Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition

Journal of the American Geriatrics Society

Volumn 53, Issue 1, 2005, Pages 83-87

  Lopez, Oscar L ^a,b   Becker, James T ^a   Saxton, Judith ^a   Sweet, Robert A ^a   Klunk, William ^a   DeKosky, Steven T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Neuropsychological Research Program   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Progression

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; HYPNOTIC AGENT; NEUROLEPTIC AGENT; SEDATIVE AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHOLINESTERASE INHIBITION; DAILY LIFE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MINI MENTAL STATE EXAMINATION; NURSING HOME; OUTCOMES RESEARCH; PSYCHOSIS; RATING SCALE; RISK FACTOR; CROSS-SECTIONAL STUDY; HOSPITAL ADMISSION; LONGITUDINAL STUDY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NURSING HOMES; PATIENT ADMISSION; RISK FACTORS; TREATMENT OUTCOME;

EID: 14544285159     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53015.x     Document Type: Article

References (24)

1. Farlow M, Gracon SI, Hershey LA et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992;268: 2523-2529.
2. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a U.S. multicentre, randomized, double-blind, placebo-controlled trual. The Donepezil Study Group. Dementia 1996;7: 293-303.
3. Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318:633-638.
4. Tariot PN, Solomon PR, Morris JC et al. A five-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276.
5. Raskind MA, Peskind ER, Wessel T et al. Galantamine in AD. A six-month, randomized, placebo-controlled trial with a six-month extension. Neurology 2000;54:2261-2268.
6. Winhlad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495.
7. Farlow M, Avand R, Messina J et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-241.
8. Doody RS, Dunn JK, Clark CM et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:295-300.
9. Knopman D, Schneider L, Davis K et al. Long-term tacrine (Cognex) treatment. Effects on nursing home placement and mortality. Neurology 1996; 47:166-177.
10. Geldmacher DS, Provenzano G, McRae T et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51:937-944.
11. Lopez OL, Becker JT, Wisniewski S et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310.
12. McKhann G, Drachman DA, Folstein MF et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
13. Lopez OL, Becker JT, Klunk W et al. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades. J Neurol 2000;55: 1854-1862.
14. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinicians. Psychiatry Res 1975;12:189-198.
15. Salmon DP, Thai LJ, Butters N et al. Longitudinal evaluation of dementia of the Alzheimer type: A comparison of 3 standardized mental status examinations. Neurology 1990;40:1225-1230.
16. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile changes in the cerebral white matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
17. Tiraboschi P, Hansen LA, Alford M et al. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology 2000; 55:1278-1283.
18. DeKosky ST, Ikonomovic MD, Styren SD et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145-155.
19. Weiner MF, Martin-Cook K, Foster BM et al. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry 2000;61:487-492.
20. Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488.
21. Lopez OL, Wisniewski SR, Becker JT et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer's disease. Arch Neurol 1999;56:1266-1272.
22. Lopez OL, Becker JT, Sweet RA et al. Patterns of change in the treatment of psychiatric symptoms in patients with probable Alzheimer's disease from 1983 to 2000. J Neuropsychiatry Clin Neurosc 2003;15:67-73.
23. Curran HV, Bond A, O'Sullivan G et al. Memory functions, alprazolam and exposure therapy: A controlled longitudinal study of agoraphobia with panic disorder. Psychol Med 1994;24:969-976.
24. Wysowski DK, Baum C, Ferguson WJ et al. Sedative-hypnotic drugs and the risk of hip fracture. J Clin Epidemiol 1996;49:111-113.